Return on Investment from the Prevention of Orphan Diseases in Kuwait
Open Access
- 1 January 2022
- journal article
- Published by Bouti Publishing in Annals of Public Health
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Early Cost-Effectiveness of Onasemnogene Abeparvovec-xioi (Zolgensma) and Nusinersen (Spinraza) Treatment for Spinal Muscular Atrophy I in The Netherlands With Relapse ScenariosValue in Health, 2021
- Methods for the Economic Evaluation of Health Care Interventions for Priority Setting in the Health System: An Update From WHO CHOICEInternational Journal of Health Policy and Management, 2021
- Applying Beta Distribution in Analyzing Bounded Outcome Score DataThe AAPS Journal, 2020
- Cost-effectiveness of Voretigene Neparvovec-rzyl vs Standard Care for RPE65-Mediated Inherited Retinal DiseaseJAMA Ophthalmology, 2019
- Preimplantation genetic diagnosis (PGD) and genetic testing for aneuploidy (PGT-A): status and future challengesGynecological Endocrinology, 2019
- Health outcomes in spinal muscular atrophy type 1 following AVXS‐101 gene replacement therapyPediatric Pulmonology, 2018
- Prevalence, incidence and carrier frequency of 5q–linked spinal muscular atrophy – a literature reviewOrphanet Journal of Rare Diseases, 2017
- Preimplantation genetic diagnosis: State of the artEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2009
- 35 years of Japanese policy on rare diseasesThe Lancet, 2008
- A robust approach for skewed and heavy-tailed outcomes in the analysis of health care expendituresJournal of Health Economics, 2006